Table 1 Correlation of PRAS40 expression to clinicopathological variables in CRC patients of Cohort 1.

From: PRAS40 promotes colorectal cancer stemness by enhancing glycolysis through triggering PGK1 acetylation

 

PRAS40 expression

 

Variables

Low level (%)

High level (%)

P value*

Total (n = 75)

18 (24.0)

57 (76.0)

 

Sex

Male (n = 42)

8 (19.0)

34 (81.0)

0.287

Female (n = 33)

10 (30.3)

23 (69.7)

 

Tumor size (cm)

>5 (n = 41)

11 (26.8)

30 (73.2)

0.595

>5 (n = 34)

7 (20.6)

27 (79.4)

 

Grade

Ⅰ-Ⅱ (n = 58)

14 (24.1)

44 (75.9)

1.000

Ⅲ-Ⅳ (n = 17)

4 (23.5)

13 (76.5)

 

Age (years)

≤66△ (n = 34)

11 (32.4)

23 (67.6)

0.175

>66 (n = 41)

7 (17.1)

34 (82.9)

 

PDL1 (H-score)

>120▽ (n = 64)

16 (25.0)

48 (75.0)

1.000

>120 (n = 11)

2 (18.2)

9 (81.8)

 

TNM stage

Ⅰ (n = 8)

5 (62.5)

3 (37.5)

 

Ⅱ (n = 17)

2 (11.8)

15 (88.2)

0.017

Ⅲ (n = 26)

4 (15.4)

22 (84.6)

0.017

Ⅳ (n = 20)

3 (15.0)

17 (85.0)

0.022

Ⅴ (n = 4)

4 (100.0)

0 (0.0)

0.49

  1. Stage I, T1-T2N0M0; stage II, T3N0M0; stage III, T4N0M0; stage IV, any T any NM0; stage V, any T any NM1. *Fisher’s exact test. △Mean age. ▽Median H-score. Significant P-values are shown in bold.
Back to article page